This webinar presentation will describe the novel approach of paired tumor/germline testing for Lynch syndrome. It will review how tumor analysis of the Lynch genes can provide additional information to help explain mismatch repair deficiency identified during Lynch syndrome screening. Basics of somatic testing and case examples will be discussed.
Kory Jasperson, MS, CGC is a Board-certified senior genetic counselor at Ambry Genetics. He has over 10 years of clinical cancer genetics experience and also completed a cancer genetics fellowship at City of Hope. Mr. Jasperson co-founded the Lynch Syndrome Screening Network (LSSN) and was previously Vice-Chair of both the Hereditary Colon Cancer Foundation and two National Comprehensive Cancer Network (NCCN) guidelines. Mr. Jasperson has over 50 research publications, many of which involve hereditary gastrointestinal cancers.
Ms. Horton received a B.S. in Biological Sciences from University of Maryland, Baltimore County. She then earned her Master of Science in Genetic Counseling at Arcadia University. She was a clinical genetic counselor in prenatal and community oncology specialties in Memphis, TN and directed the cancer genetic counseling program at The West Clinic before joining Ambry. She is a Supervisor of the Cancer Reporting team at Ambry and is involved in clinical content curation and variant assessment.
Monalyn Umali Salvador, MS, CGC received a BS in Genetics and a minor in Psychology from the University of California, Davis in 2007 and an MS in Genetic Counseling from California State University, Stanislaus in 2013. Prior to becoming a genetic counselor, she spent several years working as an assay developer in both academic and industry settings, with projects ranging from HLA genotyping to companion diagnostics for cancer therapies. She joined Ambry in 2014 as a cancer reporting genetic counselor and specializes in both somatic and hereditary oncology, with special interest in mosaicism. Additionally, she has been an integral part of the product and operational development of Ambry’s paired tumor/germline tests, including TumorNext-Lynch and TumorNext-HRD, and currently manages the somatic reporting team at Ambry.
Get in Touch
info@ambrygen.com
+1 949-900-5500 (phone)
+1 949-900-5501 (fax)
Billing
billing@ambrygen.com
+1 949-900-5795